Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib vs BAT in High Risk Essential Thrombocythemia
NCT02962388Phase 3Terminated
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Jan 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ruxolitinib in essential thrombocythemia (ET), sponsored by French Innovative Leukemia Organisation. Started Jan 2017; status: terminated.
02
Drugs
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT02962388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02962388.